In the general news, terrorists in Nigeria kidnapped hundreds of schoolgirls, leading to international outrage. Otherwise, the news flow was light.
In healthcare business news, Merck (MRK) announced a megadeal to sell its consumer unit to Bayer for $14 Billion. Boston Scientific (BSX) acquired IoGyn for $65M. Regeneron (REGN) partnered with Avalanche Biotechnologies, a gene therapy company. Pfizer (PFE) reported weak revenue, but met the bottom line on cost cutting. Apple Computer is getting into the smartphone medical app business. Lastly, Vivus’ (VVUS) diet pill Qsymia could face generic threats from Actavis.
On the data front, mouse studies showed that transfusions from younger mice somehow triggered stem cells to activate in the older mice, rejuvenating them. Also, Corcept (CORT) shares fell as its depression drug failed in Phase 3.